FDA grants fast track status to Heidelberg Pharma’s Amanitin-based ADC candidate for multiple myeloma

The Fast Track Designation was supported by nonclinical data as well as clinical results from the ongoing Phase I/IIa trial evaluating the safety and tolerability

MIRA Pharmaceuticals advances oral Ketamir-2 into Phase 1 MAD study for chemotherapy-induced neuropathic pain

Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation

Medherant announces positive Phase 1 results of clinical trial of testosterone patch for women

Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women

Elixion Biotech takes quantum-informed R&D route for next-gen precision medicines

Sigachi Industries posts Q2 FY2026 consolidated profit at Rs. 10.68 Cr

Sigachi Industries has reported total income of Rs. 112.97 crore during the period ended September 30, 2025

Dr Reddys Laboratories reports Q2 FY26 consolidated PAT at Rs. 1,437.2 Cr

Dr Reddys Laboratories has reported total income of Rs. 8,805.1 crore during the period ended September 30, 2025

ANRF, in collaboration with ICMR and Gates Foundation, launches Maha MedTech Mission

With milestone-linked funding of Rs. 5–25 crore per project (and up to Rs. 50 crore in exceptional cases), the Mission will support projects that bring impactful MedTech solutions to market

Merck KGaA reports long-term OGSIVEO phase 3 data demonstrating sustained efficacy and safety in desmoid tumors

Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile

Europe is putting vital medicines at risk by allowing ‘carbon heavy’ imports from the Far East: INEOS

INEOS production of BDO in Germany, which produces a vital ingredient for antibiotics, statins and vitamin B6, is being crushed by a flood of carbon heavy imports and product dumping from the Far East

Laurus Labs posts Q2 FY26 consolidated PAT higher at Rs. 195 Cr

Laurus Labs has reported total income of Rs. 1,680.43 crore during the period ended September 30, 2025